secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2022-03-08T23:59:59+00:00
Accession:  0001193125-22-068800
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma enters $100M term loan facility with BPCR Limited Partnership
---------------------------------------------------------------------------

- Term loans up to $100M; Tranche A $75M at closing, Tranche B $25M optional by Dec 31, 2022.
- Interest rate 8.25% + 3-month LIBOR (floor 1.25%); quarterly interest; principal amortization starts after 17th quarter.
- Secured by substantially all assets; no financial covenants; prepayment premiums (3%/2%/1%) and makewhole provisions.
- Proceeds for general corporate and working capital; loan matures 5 years from Tranche A closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522068800/0001193125-22-068800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312522068800/d302602d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-068800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer